+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Abemaciclib"

Cancer CDK Inhibitors Market Report 2025 - Product Thumbnail Image

Cancer CDK Inhibitors Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
From
Synovial Sarcoma Pipeline Analysis Report - Product Thumbnail Image

Synovial Sarcoma Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035 - Product Thumbnail Image

Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035

  • Report
  • January 2024
  • 157 Pages
  • Global
From
From
From
From
From
From
From
  • 15 Results (Page 1 of 1)
Loading Indicator

Abemaciclib is a type of oncology drug used to treat certain types of cancer. It is a cyclin-dependent kinase (CDK) inhibitor, which works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Abemaciclib is used in combination with other cancer treatments, such as hormone therapy, chemotherapy, and targeted therapy. It is approved for the treatment of advanced or metastatic breast cancer, as well as for the treatment of non-small cell lung cancer. Abemaciclib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2017. It is the first CDK inhibitor to be approved for the treatment of advanced or metastatic breast cancer. Since its approval, it has become an important part of the oncology drug market. Several companies are involved in the Abemaciclib market, including Eli Lilly and Company, Novartis, and Pfizer. These companies are involved in the research, development, and marketing of Abemaciclib. Show Less Read more